Sinopharm Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Wanyong Lian
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | 3.8yrs |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CEO
Wanyong Lian (53 yo)
less than a year
Tenure
Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President & Executive Director | less than a year | no data | no data | |
Chief Financial Officer | 3.8yrs | no data | no data | |
Secretary to the Board | 6yrs | no data | no data |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Management: X2S's management team is considered experienced (3.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President & Executive Director | less than a year | no data | no data | |
Non-Executive Vice Chairman | 14.6yrs | no data | no data | |
Non-Executive Director | 3.5yrs | no data | no data | |
Chief Supervisor | 3.5yrs | no data | no data | |
Independent Non-Executive Director | 4.3yrs | CN¥350.00k | no data | |
Independent Non-Executive Director | 4.3yrs | CN¥350.00k | no data | |
Non-Executive Chairman | less than a year | no data | no data | |
Non-Executive Director | 7.3yrs | no data | no data | |
Independent Non-Executive Director | 6yrs | CN¥350.00k | no data | |
Non Executive Director | 4.5yrs | no data | no data | |
Independent Non-Executive Director | 4.3yrs | CN¥350.00k | no data | |
Non-executive Director | 1.3yrs | no data | no data |
4.3yrs
Average Tenure
53yo
Average Age
Experienced Board: X2S's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 01:05 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinopharm Group Co. Ltd. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Mann | Barclays |
Derrick Sun | BNP Paribas Securities (Asia) |
Bo Li | BofA Global Research |